Developments in IBD ...If you are following the developments in IBD, you may have realized a few things are tied in well to ATE's past year and a half.
You may have seen the work on Si-based hydrogen release to reduce ROS and improve UC conditions.
You may wonder if H2 release is as important or more important than H2S release.
Maybe there are other considerations that ATE is investigating (with the help of companies like Dalriada).
But - if true - ROS and the intestines sounds an awful lot like ROS concerns experienced at the liver (OTENA).
Regardless ... I am curious to see where IBD development is going. It has been delayed quarterly for at least 3 quarters (going on 4) and no one will discuss it. Is it solely related to IBD development or are we trying to kill two diseased birds with one ROS killing stone ?
Could this learning go a long way to help with IBD while also help OTENA do its job in chronic pain ?
I honestly have no clue - but - there do seem to be some very interesting developments and connections that make me wonder what's really happening behind the scenes.
Unfortunately ... no one is going to tell us until the time is right. That's the way it is. If it were easy, everyone would be doing it. : )
-------------------------
For your reading pleasure ...
"Because one of the disease pathogenesis is involvement of oxidative stress, it is likely that an appropriate antioxidant will be an effective therapeutic agent for UC." "One of UC pathogenesis is the oxide accumulation in the intestinal mucosa caused by reactive oxygen species (ROS), which have a strong oxidizing effect2. The accumulation of such oxides affects various transcriptional activities and phosphorylation signals, thereby causing inflammation." https://www.nature.com/articles/s41598-022-13655-7